Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease

References

• Hanauer SB, Sandborn WJ, Rutgeerts P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–333.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC-II trial. Gut. 2007;56:1232–1239.
   PubMed Web of Science ®Google Scholar
• Cohen BL, Sachar DB. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017;357:j2505.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Panaccione R, Mallarkey G. Review: efficacy and safety of adalimumab in Crohn’s disease. Therap Adv Gastroenterol. 2008;1:43–50.
   PubMedGoogle Scholar
• Sehgal P, Colombel JF, Narula N. Adverse events during anti-TNFα therapies in IBD (excluding infections and malignancies): when to stop, continue, or switch therapies. Inflamm Bowel Dis. 2016;22:257–265.
   PubMed Web of Science ®Google Scholar
• Ordás I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012;10:1079–1087.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Cheifetz AS, Zittan E, et al. Higher adalimumab drug levels are associated with mucosal healing in patients with Crohn’s disease. J Chrons Colitis. 2016;10:507–509.
   PubMedGoogle Scholar
• Zittan E, Kabakchiev B, Milgrom R, et al. Higher adalimumab drug levels are associated with mucosal healing in patients with Crohn's disease. J Crohns Colitis. 2016;10:510–515.
   PubMedGoogle Scholar
• Juncadella A, Papamichael K, Vaughn BP, et al. Maintenance adalimumab concentrations are associated with biochemical, endoscopic, and histologic remission in inflammatory bowel disease. Dig Dis Sci. 2018;63(11):3067–3073.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Vermeire S, Lambrecht G, et al. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn’s disease. Gastroenterology. 2018;154(5):1343–1351.
   PubMed Web of Science ®Google Scholar
• Casteele NV, Ferrante M, Assche GV, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320–1329.e3.
   PubMed Web of Science ®Google Scholar
• Assa A, Matar M, Turner D, et al. OP18 Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn’s disease: the paediatric Crohn’s disease adalimumab-level-based optimisation treatment (PAILOT) trial. J Crohn’s Colitis. 2019;13:S012–S013.
   Google Scholar
• Brandse JF, Vos LMC, Jansen J, et al. Serum concentration of anti-TNF antibodies, adverse effects and quality of life in patients with inflammatory bowel disease in remission on maintenance treatment. J Chrons Colitis. 2015;9:973–981.
   PubMed Web of Science ®Google Scholar
• Greener T, Kabakchiev B, Steinhart AH, et al. Higher infliximab levels are not associated with an increase in adverse events in inflammatory bowel disease. Inflamm Bowel Dis. 2018;24:1808–1814.
   PubMed Web of Science ®Google Scholar
• Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304–2316.
   PubMed Web of Science ®Google Scholar
• Dignass A, Stoynov S, Dorofeyev AE, et al. Once versus three times daily dosing of oral budesonide for active Crohn’s disease: a double-blind, double-dummy, randomised trial. J Crohns Colitis. 2014;8:970–980.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Assche G, Van Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–265.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Panaccione R, et al. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis. 2013;19(8):1700–1709.
   PubMed Web of Science ®Google Scholar
• Motoya S, Watanabe M, Wallace K, et al. Efficacy and safety of dose escalation to adalimumab 80 mg every other week in Japanese patients with Crohn’s disease who lost response to maintenance therapy. Inflamm Intest Dis. 2017;2:228–235.
   Google Scholar
• Pelletier A-L, Nicaise-Roland P. Adalimumab and pharmacokinetics: impact on the clinical prescription for inflammatory bowel disease. World J Pharmacol. 2016;5:44–50.
   Google Scholar
• Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–936.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1385–1397.
   PubMed Web of Science ®Google Scholar
• Shah ED, Farida JP, Siegel CA, et al. Risk for overall infection with anti-TNF and anti-integrin agents used in IBD: a systematic review and meta-analysis. Inflamm Bowel Dis. 2017;23:570–577.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Hibi T, Lomax KG, et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohns Colitis. 2012;6:160–173.
   PubMed Web of Science ®Google Scholar
• Bejan-Angoulvant T, Ternant D, Daoued F, et al. Brief report: relationship between serum infliximab concentrations and risk of infections in patients treated for spondyloarthritis. Arthritis Rheumatol. 2017;69:108–113.
   PubMed Web of Science ®Google Scholar
• Drobne D, Kurent T, Golob S, et al. Success and safety of high infliximab trough levels in inflammatory bowel disease. Scand J Gastroenterol. 2018;53:940–946.
   PubMed Web of Science ®Google Scholar
• McLean LP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol. 2014;8:223–240.
   PubMed Web of Science ®Google Scholar
• Fréling E, Baumann C, Cuny JF, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol. 2015;110:1186–1196.
   PubMed Web of Science ®Google Scholar
• Moran GW, Lim AWK, Bailey JL, et al. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:1002–1024.
   PubMed Web of Science ®Google Scholar
• Coutzac C, Chapuis J, Poullenot F, et al. Association between infliximab trough levels and the occurrence of paradoxical manifestations in patients with inflammatory bowel disease: a case-control study. J Crohns Colitis. 2015;9:982–987.
   PubMed Web of Science ®Google Scholar
• Huang VWM, Dhami N, Fedorak D, et al. A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels. Can J Gastroenterol Hepatol. 2015;29:35–40.
   PubMed Web of Science ®Google Scholar